The Canadian Intellectual Property Office (CIPO) Issues Notice of Allowance for Patent Covering Palisade Bio’s PALI-2108 for Treating Ulcerative Colitis
Shots:
- The CIPO has issued Notice of Allowance to the patent application no. 3,174,137 entitled, ‘Gut Microbiota Bioactivated PDE4 Inhibitor Precursors’, covering the formulation of PALI-2108
- PALI-2108 consists of a galactose-derived sugar moiety which upon cleavage by colonic bacterium enzyme β-glucuronidase enabled localized bioactivation & colon-specific distribution with limited systemic exposure, verified in its tissue distribution study. It further decreased DAI score & body wt. across certain dosage group in non-clinical study of DSS-induced UC mouse model
- Based on these efficacy outcomes, the company anticipates commencement of P-I study investigating PALI-2108 (oral) to treat moderate-to-severe UC during H2’24
Ref: Palisade | Image: Palisade
Related News:- Palisade Bio Reports P-II Study (PROFILE) Results of LB1148 for Post-Surgical Abdominal Adhesions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
